226 related articles for article (PubMed ID: 19802980)
1. In-vitro activity of ceftazidime against Pseudomonas aeruginosa: and its stability to pseudomonal beta-lactamases.
Livermore DM; Williams RJ; Williams JD
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():163-7. PubMed ID: 19802980
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the beta-lactamase stability and the in-vitro activity of cefoperazone, cefotaxime, cefsulodin, ceftazidime, moxalactam and ceftriaxone against Pseudomonas aeruginosa.
Livermore DM; Williams RJ; Williams JD
J Antimicrob Chemother; 1981 Oct; 8(4):323-31. PubMed ID: 6271726
[No Abstract] [Full Text] [Related]
3. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
[TBL] [Abstract][Full Text] [Related]
4. Comparative in-vitro activity of ceftazidime (GR 20263) and other beta-lactamase stable cephalosporins against pseudomonas. Effect of inoculum size and divalent cation supplementation.
Chow AW; Bartlett KH
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():345-8. PubMed ID: 19803012
[TBL] [Abstract][Full Text] [Related]
5. Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
Phillips I; Warren C; Shannon K; King A; Hanslo D
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():23-31. PubMed ID: 19802967
[TBL] [Abstract][Full Text] [Related]
6. An in-vitro comparison of new cephalosporins with special reference to Pseudomonas aeruginosa.
van Klingeren B
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():97-105. PubMed ID: 19810171
[TBL] [Abstract][Full Text] [Related]
7. Activity of cefpirome (HR810) against Pseudomonas aeruginosa strains with characterised resistance mechanisms to beta-lactam antibiotics.
Gargalianos P; Oppenheim BA; Skepastianos P; Livermore DM; Williams RJ
J Antimicrob Chemother; 1988 Dec; 22(6):841-8. PubMed ID: 3149631
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of ceftazidime and other cephalosporins to a range of beta-lactamases and their potential as inducing agents.
Mouton RP; Bongaerts GP; van Gestel MH
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():147-52. PubMed ID: 19802978
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of beta-lactam resistance in British isolates of Pseudomonas aeruginosa.
Williams RJ; Livermore DM; Lindridge MA; Said AA; Williams JD
J Med Microbiol; 1984 Jun; 17(3):283-93. PubMed ID: 6327987
[TBL] [Abstract][Full Text] [Related]
10. Cefoperazone against carbenicillin-resistant isolates of Pseudomonas aeruginosa: comparison with other newer cephalosporins and N-formimidoyl thienamycin.
Chau PY; Ling J; Ng WS
J Antimicrob Chemother; 1983 Oct; 12(4):337-45. PubMed ID: 6417100
[TBL] [Abstract][Full Text] [Related]
11. In-vitro activity of ceftazidime, a beta-lactamase stable cephalosporin.
Neu HC
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():131-4. PubMed ID: 19810175
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
Philippon A
Chemioterapia; 1985 Dec; 4(6):424-8. PubMed ID: 3938346
[TBL] [Abstract][Full Text] [Related]
13. Comparative in-vitro activity of cefsulodin and ceftazidime against ticarcillin-resistant Pseudomonas aeruginosa.
Philippon A; Paul G; Nevot P
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():119-22. PubMed ID: 19810173
[TBL] [Abstract][Full Text] [Related]
14. Laboratory mutants of OXA-10 beta-lactamase giving ceftazidime resistance in Pseudomonas aeruginosa.
Danel F; Hall LM; Livermore DM
J Antimicrob Chemother; 1999 Mar; 43(3):339-44. PubMed ID: 10223588
[TBL] [Abstract][Full Text] [Related]
15. The in-vitro activity of three anti-pseudomonal cephalosporins against isolates from patients with cystic fibrosis.
Kelly N; Falkiner FR; Keane CT; Murphy M; Fitzgerald MX
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():175-8. PubMed ID: 19802982
[TBL] [Abstract][Full Text] [Related]
16. OXA-16, a further extended-spectrum variant of OXA-10 beta-lactamase, from two Pseudomonas aeruginosa isolates.
Danel F; Hall LM; Gur D; Livermore DM
Antimicrob Agents Chemother; 1998 Dec; 42(12):3117-22. PubMed ID: 9835501
[TBL] [Abstract][Full Text] [Related]
17. Influence of bacterial beta-lactamase production on susceptibility in agar or broth to new cephalosporins.
Adamsson L; Dornbusch K; Hallander HO
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():153-62. PubMed ID: 19802979
[TBL] [Abstract][Full Text] [Related]
18. [Pseudomonas aeruginosa: acquired in vitro resistance to beta-lactams].
Thabaut A; Meyran M
Pathol Biol (Paris); 1983 May; 31(5):387-91. PubMed ID: 6413939
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of in vitro bacteriostatic effect of five betalactamins against Pseudomonas aeruginosa (author's transl)].
Lesage D; Delisle-Mizon F; Denis C; Vergez P; Daguet GL
Pathol Biol (Paris); 1982 Jun; 30(6):440-3. PubMed ID: 6213917
[TBL] [Abstract][Full Text] [Related]
20. [Comparative effect of beta-lactam activity on Pseudomonas aeruginosa as a function of resistance phenotypes].
Thabaut A; Philippon A; Meyran M
Presse Med; 1984 Mar; 13(13):768-71. PubMed ID: 6231592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
